Equine arteritis virus-neutralizing antibody in the horse is induced by a determinant on the large envelope glycoprotein GL.

This research discusses the identification of a key component in the equine arteritis virus (EAV) that causes a response in horse immune systems. It suggests that this component could be used for diagnostic tests and vaccines.

Introduction to the Research

• The study focuses on identifying certain portions (ORFs 2 to 7) of the equine arteritis virus (EAV), a sexually transmitted disease in horses leading to various health issues like respiratory illness and abortion.
• For the experiment, the researchers utilized complementary DNAs encoding the said ORFs and cloned them into an expression vector known as pGEX to produce fusion proteins.

Methodology and Process

• These fusion proteins were then purified using an affinity purification technique, a method where targeted proteins are selectively isolated from a mixture, increasing the purity of the result.
• The researchers applied an enzyme-linked immunosorbent assay (ELISA) using horse blood serum to these purified proteins. This test is used to detect and measure antibodies in blood and identify immunoreactive polypeptides or sections of the virus that causes an immune response.

Key Findings

• The large envelope glycoprotein (GL), a component of EAV, appeared to be highly reactive to the horse’s immune systems.
• Further analysis allowed the researchers to map an immuno-dominant epitope, a section of the protein that the immune system recognizes, between amino acids 55 and 98 of the GL protein.
• A fusion protein covering this region and a GL-specific synthetic peptide (residues 75 through 97) caused the horse’s immune system to produce EAV-neutralizing antibodies when used as a vaccine.

Implications and Conclusions

• This specific region of GL seems prone to exposure on the surface of the EAV virion or virus particle, making it a viable target for the immune system.
• Thus, it may be used for diagnostic tests to identify EAV infection or to develop vaccines to combat EAV in horses.